Micro Interventional Devices, Inc. - "Permaseal TM"

Angio Consult is consulting partner of the US company Micro Interventional Devices, Inc. (MID), which distributes its transapical access and closure device "Permaseal TM" via our mother company Angiopro.

"Permaseal TM" is delivered to the myocardial surface of the heart via mini-thoracotomy. The product is designed to facilitate access to the left ventricle for delivery sheaths and/or catheters of up to 30F. Once the 30F or smaller device is removed from the ventricle, Permaseal is used to close the access site.

Permaseal allows for a minimally invasive footprint that is reproducible time and time again, regardless of the operator. The device is designed to allow for the passage of different instrument sizes, comply with the beating heart so as not to interfere with wall motion and leave little foreign material behind. This reliable access and closure approach may reduce OR time, abate blood loss, and simplify complex structural heart repair procedures, ultimately enabling a conversion from surgical procedures to fully percutaneous catheter lab-based procedures and reducing the learning curve associated with these procedures.

No other transapical closure device delivers all of the following benefits:

  • Minimally invasive access
  • Easy, reliable and reproducible deployments
  • Conformity to different instrument sizes
  • Compliance with the beating heart
  • Little foreign material left behind
  • Results that meet or exceed the current standard of care

The CE marking is expected for April 2016.

Press Releases

Transapical access for transcatheter aortic valve implantation (TA-TAVI) has become a routine procedure for patients at high surgical risk and is a valid alternative to transfemoral TAVI. Transapical access has seen little standardization of technique due to the absence of automated preclosure and carries a risk for bleeding complications.

Read more (PDF)

Transapical access for transcatheter aortic valve implantation (TA-TAVI) has become a routine procedure for patients at high surgical risk and is a valid alternative to transfemoral TAVI. Transapical access has seen little standardisation of technique due to the absence of automated preclosure and carries a risk for bleeding complications.

Read more (PDF)

BioStable Science & Engineering, Inc.

Our partner company BioStable Science & Engineering, Inc., based in Austin, Texas, is developing innovative products for the treatment of cardiovascular disease and focuses on aortic repair with their HAART™-technology.
The HAART™ aortic valve ring allows for patients to regenerate and stabilizem whose aortic valves function is insufficient or who suffer from a thoracic aortic aneurysm. By making use of the HAART™-technology, the heart valves of the patients will be obtained rather than replaced.
 
The device is designed as a tree dimensional annuloplasty ring which consists of a one-piecve titanium construction and is coated with dacron fabric.

The system has the following advantages:

  • Permanent preservation of the leaking aortic valves
  • Possibility of a valves reconstruction, even in the case of very complex surgeries i.e. artic root replacement/ aortic root surgeries
  • Perfect obturation and constriction of the damaged aortic valve
  • The individual fitting to the respective heart valve guarantees a higher success rate
  • No enduring medication (such as blood thinner) needed

At the moment, Angio Consult supports BioStable with the market entry of their products in the German-speaking world.

TVA Medical, Inc.

TVA Medical (Austin, Texas) developed the first catheter system to place an AV shunt for hemodiaysis patients endovascularly.

Its inventor is Dr. Billy Cohn, a true innovator who holds many patents and a practising cardiac surgeon at the Texas Heart Institute. The everlinQ System has CE-mark and Angio Consult is commissioned to take care of the European launch and everything that comes with it: admissions, reimbursement, study and procedure support, congress management and reseach papers as well as the preparation for the commercial launch.

AngioConsult is TVA Medical's partner since 2013.

Meditreat

Special service provider for the preparation of medical devices for electrophysiology

Angio Consult is your ideal consultant when it comes to cost efficiency. Together with our partner Meditreat GmbH we offer you the certified preparation of medical devices considering all important economical and ecological aspects.

The specially developed, validated and certified procedure offers the highest possible degree of safety and quality regarding the protection goals for users, patients and third parties - as enshrined in the medical device operator regulation.
Its foundation is the EN ISO 13485 certification including the highest risk category "kritisch C".
The respective federal state authorities monitor the preparation and the complioance of the statutory provisions.
We are glad to present your individual benefits to you in a one-to-one appointment.